| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.10.24 | Celldex Therapeutics' Barzolvolimab Meets Phase 2 Study Endpoints For Chronic Inducible Urticaria | 601 | AFX News | WASHINGTON (dpa-AFX) - Celldex Therapeutics Inc. (CLDX) announced that barzolvolimab met all primary and secondary endpoints with high statistical significance in a positive Phase 2 study targeting... ► Artikel lesen | |
| 27.10.24 | Novartis Announces Promising 12-Month Results For Fabhalta In C3 Glomerulopathy | 693 | AFX News | BASEL (dpa-AFX) - Novartis (NVS) presented 12-month data from the Phase III APPEAR-C3G study at the American Society of Nephrology or ASN Kidney Week 2024. The results showed that patients with... ► Artikel lesen | |
| 27.10.24 | Biogen's Phase 2 Study Shows Promising Results For Felzartamab In IgA Nephropathy | 632 | AFX News | WESTON (dpa-AFX) - Biogen Inc. (BIIB) announced that results from the Phase 2 IGNAZ study evaluating felzartamab, an investigational anti-CD38 monoclonal antibody, in individuals with IgA nephropathy... ► Artikel lesen |
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| NVIDIA | 2.032 |
| NOVO NORDISK | 1.964 |
| PUMA | 1.776 |
| D-WAVE QUANTUM | 1.493 |
| BAYER | 1.489 |
| TUI | 1.468 |
| EVOTEC | 1.464 |
| DEUTSCHE BANK | 1.079 |
| BASF | 1.013 |
| RHEINMETALL | 944 |
| VARTA | 914 |
| NEL | 892 |
| TESLA | 880 |
| RENK GROUP | 852 |
| PLUG POWER | 834 |
| COMMERZBANK | 782 |
| THYSSENKRUPP | 721 |
| SIEMENS ENERGY | 689 |
| MEDIGENE | 664 |
| BIONTECH | 663 |
| VOLKSWAGEN | 633 |
| HEIDELBERGER DRUCK | 626 |
| DEUTSCHE TELEKOM | 624 |
| DEUTSCHE LUFTHANSA | 623 |
| BYD | 611 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
